PCSK9 Inhibitor
Daily oral PCSK9 inhibitor cut LDL cholesterol by 50% over 12 weeks
CHICAGO — In a phase 2b study, treatment with a once-daily oral PCSK9 inhibitor added to statin therapy resulted in a more than 50% reduction in LDL cholesterol at 12 weeks in patients with hypercholesterolemia.
Breaking down barriers: How to optimize access, use of PCSK9 inhibitors
Over the years, there have been significant changes to the dyslipidemia medication management guidelines, alongside increasing evidence for novel cholesterol-lowering medications, including PCSK9 inhibitors.
PCSK9 Inhibitors
Nonstatins- Evolving Role in ASCVD Prevention
Evolocumab shows particular CV benefit in those with autoimmune disease, inflammation
Patients with atherosclerosis and elevated LDL plus autoimmune or inflammatory disease may derive particular CV benefit from PCSK9 inhibition with evolocumab, a speaker reported.
Insurers reject PCSK9 inhibitors at a higher rate vs. other cardiometabolic prescriptions
PCSK9 inhibitors are rejected by insurance providers at a higher rate compared with other guideline-indicated cardiometabolic drugs despite expanded labeling and reduced manufacturer cost, researchers reported.
Webcast: Identifying and Addressing Elevated Sodium Intake to Decrease Cardiovascular Risk
This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.
Challenges and Solutions in Lipid-Lowering Therapy in Women: From Gaps to Practice-Changing Advances
This activity is supported by an educational grant from Esperion Therapeutics, Inc.
Novel PCSK9 inhibitor recaticimab linked to durable LDL reduction
PHILADELPHIA — Recaticimab, a novel anti-PCSK9 drug, conferred significant LDL reductions at 48 weeks in a cohort of patients with mixed hyperlipidemias already on statin therapy, a speaker reported.
Early study suggests gene editing can lower LDL cholesterol via PCSK9 inhibition
PHILADELPHIA — A novel single-dose CRISPR base-editing infusion for patients with heterozygous familial hypercholesterolemia and advanced CAD reduced serum PCSK9 and lowered LDL by up to 55% in one patient, a speaker reported.